Just another negative study, adding to the scores of others that to date, have found no link between vaccines, or any component of vaccines, to autism.
http://pediatrics.aappublications.org/cgi/content/abstract/peds.2010-0309v1
Published online September 13, 2010
PEDIATRICS (doi:10.1542/peds.2010-0309)
Prenatal and Infant Exposure to Thimerosal From Vaccines and Immunoglobulins and Risk of Autism
Cristofer S. Price, ScMa, William W. Thompson, PhDb, Barbara Goodson, PhDa, Eric S. Weintraub, MPHc, Lisa A. Croen, PhDd, Virginia L. Hinrichsen, MS, MPHe, Michael Marcy, MDf, Anne Robertson, PhDa, Eileen Eriksen, MPHf, Edwin Lewis, MPHd, Pilar Bernal, MDg, David Shay, MD, MPHh, Robert L. Davis, MD, MPHi, Frank DeStefano, MD, MPHc
aAbt Associates Inc, Cambridge, Massachusetts;
bNational Center for Chronic Disease Prevention and Health Promotion,
cImmunization Safety Office, and
hInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia;
dDivision of Research, Kaiser Permanente Northern California, Oakland, California;
gDepartment of Psychiatry and Behavioral Sciences, Kaiser Permanente ASD Center San Jose Northern California Region, Stanford University, Palo Alto, California;
eDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts;
fSouthern California Kaiser Permanente, and Center for Vaccine Research, University of California, Los Angeles, California; and
iCenter for Health Research Southeast, Kaiser Permanente, Atlanta, Georgia
Objective Exposure to thimerosal, a mercury-containing preservative that is used in vaccines and immunoglobulin preparations, has been hypothesized to be associated with increased risk of autism spectrum disorder (ASD). This study was designed to examine relationships between prenatal and infant ethylmercury exposure from thimerosal-containing vaccines and/or immunoglobulin preparations and ASD and 2 ASD subcategories: autistic disorder (AD) and ASD with regression.
Methods A case-control study was conducted in 3 managed care organizations (MCOs) of 256 children with ASD and 752 controls matched by birth year, gender, and MCO. ASD diagnoses were validated through standardized in-person evaluations. Exposure to thimerosal in vaccines and immunoglobulin preparations was determined from electronic immunization registries, medical charts, and parent interviews. Information on potential confounding factors was obtained from the interviews and medical charts. We used conditional logistic regression to assess associations between ASD, AD, and ASD with regression and exposure to ethylmercury during prenatal, birth-to-1 month, birth-to-7-month, and birth-to-20-month periods.
Results There were no findings of increased risk for any of the 3 ASD outcomes. The adjusted odds ratios (95% confidence intervals) for ASD associated with a 2-SD increase in ethylmercury exposure were 1.12 (0.831.51) for prenatal exposure, 0.88 (0.621.26) for exposure from birth to 1 month, 0.60 (0.360.99) for exposure from birth to 7 months, and 0.60 (0.320.97) for exposure from birth to 20 months.
Conclusions In our study of MCO members, prenatal and early-life exposure to ethylmercury from thimerosal-containing vaccines and immunoglobulin preparations was not related to increased risk of ASDs.
Key Words: thimerosal mercury vaccines immunoglobulins autism
Abbreviations: CDC = Centers for Disease Control and Prevention MCO = managed care organization ASD = autism spectrum disorder TCI = thimerosal-containing injection AD = autistic disorder ADI-R = Autism Diagnostic Interview-Revised ADOS = Autism Diagnostic Observation Schedule SCQ = Social Communication Questionnaire OR = odds ratio Hib = Haemophilus influenzae type b
http://pediatrics.aappublications.org/cgi/content/abstract/peds.2010-0309v1
Published online September 13, 2010
PEDIATRICS (doi:10.1542/peds.2010-0309)
Prenatal and Infant Exposure to Thimerosal From Vaccines and Immunoglobulins and Risk of Autism
Cristofer S. Price, ScMa, William W. Thompson, PhDb, Barbara Goodson, PhDa, Eric S. Weintraub, MPHc, Lisa A. Croen, PhDd, Virginia L. Hinrichsen, MS, MPHe, Michael Marcy, MDf, Anne Robertson, PhDa, Eileen Eriksen, MPHf, Edwin Lewis, MPHd, Pilar Bernal, MDg, David Shay, MD, MPHh, Robert L. Davis, MD, MPHi, Frank DeStefano, MD, MPHc
aAbt Associates Inc, Cambridge, Massachusetts;
bNational Center for Chronic Disease Prevention and Health Promotion,
cImmunization Safety Office, and
hInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia;
dDivision of Research, Kaiser Permanente Northern California, Oakland, California;
gDepartment of Psychiatry and Behavioral Sciences, Kaiser Permanente ASD Center San Jose Northern California Region, Stanford University, Palo Alto, California;
eDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts;
fSouthern California Kaiser Permanente, and Center for Vaccine Research, University of California, Los Angeles, California; and
iCenter for Health Research Southeast, Kaiser Permanente, Atlanta, Georgia
Objective Exposure to thimerosal, a mercury-containing preservative that is used in vaccines and immunoglobulin preparations, has been hypothesized to be associated with increased risk of autism spectrum disorder (ASD). This study was designed to examine relationships between prenatal and infant ethylmercury exposure from thimerosal-containing vaccines and/or immunoglobulin preparations and ASD and 2 ASD subcategories: autistic disorder (AD) and ASD with regression.
Methods A case-control study was conducted in 3 managed care organizations (MCOs) of 256 children with ASD and 752 controls matched by birth year, gender, and MCO. ASD diagnoses were validated through standardized in-person evaluations. Exposure to thimerosal in vaccines and immunoglobulin preparations was determined from electronic immunization registries, medical charts, and parent interviews. Information on potential confounding factors was obtained from the interviews and medical charts. We used conditional logistic regression to assess associations between ASD, AD, and ASD with regression and exposure to ethylmercury during prenatal, birth-to-1 month, birth-to-7-month, and birth-to-20-month periods.
Results There were no findings of increased risk for any of the 3 ASD outcomes. The adjusted odds ratios (95% confidence intervals) for ASD associated with a 2-SD increase in ethylmercury exposure were 1.12 (0.831.51) for prenatal exposure, 0.88 (0.621.26) for exposure from birth to 1 month, 0.60 (0.360.99) for exposure from birth to 7 months, and 0.60 (0.320.97) for exposure from birth to 20 months.
Conclusions In our study of MCO members, prenatal and early-life exposure to ethylmercury from thimerosal-containing vaccines and immunoglobulin preparations was not related to increased risk of ASDs.
Key Words: thimerosal mercury vaccines immunoglobulins autism
Abbreviations: CDC = Centers for Disease Control and Prevention MCO = managed care organization ASD = autism spectrum disorder TCI = thimerosal-containing injection AD = autistic disorder ADI-R = Autism Diagnostic Interview-Revised ADOS = Autism Diagnostic Observation Schedule SCQ = Social Communication Questionnaire OR = odds ratio Hib = Haemophilus influenzae type b



